A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

NCT07681596 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

101

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

BIOLOGICAL: AZD4045
DRUG: Daratumumab
DRUG: Aldesleukin

Sponsor

AstraZeneca